MTHFR Deficiency and Autism Spectrum Disorder
Routine MTHFR genetic testing is NOT recommended for patients with autism spectrum disorder, as current guidelines explicitly state there is insufficient evidence to support this practice. 1
Key Guideline Recommendations
The 2013 ACMG guidelines for clinical genetics evaluation in ASD clearly list "methylation/epigenetic testing" among genetic tests that have insufficient evidence to recommend routine testing 1. This directly addresses MTHFR-related testing in the autism population.
What Testing IS Recommended
All patients with ASD should be offered:
- Referral to clinical genetics evaluation 1
- Comprehensive dysmorphology examination by a clinical geneticist
- Tiered genetic testing based on clinical findings (chromosomal microarray, fragile X testing when indicated)
- Formal audiogram to rule out hearing loss 1
The genetic evaluation should be customized to the individual clinical situation rather than following a one-size-fits-all approach 1.
The MTHFR Controversy
While recent research studies (2024-2026) have explored associations between MTHFR polymorphisms and ASD 2, 3, 4, 5, these are not yet incorporated into clinical practice guidelines. The evidence shows:
- MTHFR C677T and MTRR A66G variants may be associated with increased ASD risk 3
- Lower MTHFR activity correlates with more severe ASD symptoms in some cohorts 4
- However, these findings come from small studies with limited sample sizes 4
Critical caveat: The MTHFR 677T allele actually showed a protective effect in one recent study, with higher frequency in controls (50%) versus ASD patients (37.67%) 5. This contradictory evidence underscores why routine testing is not recommended.
When to Consider Metabolic Testing
Only pursue folate/B12 metabolic workup if:
- Clinical suspicion of true vitamin deficiency exists (dietary restriction, malabsorption)
- Elevated homocysteine is detected (≥15 μM) 6
- Neurological symptoms suggest B12 deficiency 7
If Metabolic Testing is Pursued
Laboratory evaluation should include:
- Serum and erythrocyte folate levels
- Serum cobalamin (B12)
- Serum/urine methylmalonic acid 6
- Total plasma homocysteine (fasting, ≥8 hours) 6
Do NOT supplement with folate alone before ruling out B12 deficiency, as this can mask hematologic findings while allowing irreversible neurological damage to progress 6, 7.
Supplementation Approach (If Deficiency Confirmed)
Vitamin B12 Treatment
For confirmed B12 deficiency:
- Intramuscular/subcutaneous injection: 100 mcg daily for 6-7 days 7
- Then alternate days for 7 doses
- Then every 3-4 days for 2-3 weeks
- Maintenance: 100 mcg monthly for life 7
Avoid IV route - results in urinary loss of vitamin 7
Folate Considerations
- Address B12 status first 7
- If folate deficiency confirmed, supplement concomitantly 7
- Recent trials suggest leucovorin (folinic acid) may benefit selected ASD children with documented folate deficiency 8
- Methylcobalamin (mB12) injections at 64.5-75 μg/kg/dose showed improvements in methylation markers and clinical symptoms in research settings 9
Monitoring Response
If treatment is initiated, monitor:
- Hematocrit and reticulocyte counts (daily days 5-7, then frequently until normal) 7
- Total homocysteine levels
- Methylmalonic acid (if B12 deficiency present)
- Clinical symptoms: communication, daily living skills, social skills 9
Common adverse effects with B12 treatment (generally mild): hyperactivity (11.9%), trouble sleeping (7.6%), irritability (3.4%) 9
Bottom Line Algorithm
- Do NOT order routine MTHFR genetic testing for ASD patients 1
- DO refer all ASD patients to clinical genetics for comprehensive evaluation 1
- Only pursue metabolic testing if clinical signs of vitamin deficiency or elevated homocysteine
- If testing metabolic status: Check folate, B12, methylmalonic acid, and homocysteine together 6
- If deficiency confirmed: Treat B12 first (if low), then add folate 7
- Monitor response with labs and clinical assessment
The focus should remain on evidence-based genetic evaluation through clinical genetics consultation, not on unproven MTHFR screening that lacks guideline support.